89 related articles for article (PubMed ID: 8566106)
21. Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans.
Walsh SL; Strain EC; Abreu ME; Bigelow GE
Psychopharmacology (Berl); 2001 Sep; 157(2):151-62. PubMed ID: 11594439
[TBL] [Abstract][Full Text] [Related]
22. Neuroprotective effect of the kappa-agonist enadoline (CI-977) in rat models of focal cerebral ischaemia.
Hayward NJ; McKnight AT; Woodruff GN
Eur J Neurosci; 1993 Jul; 5(7):961-7. PubMed ID: 8281306
[TBL] [Abstract][Full Text] [Related]
23. Cocaine modulates allosteric D
Beggiato S; Borelli AC; Borroto-Escuela D; Corbucci I; Tomasini MC; Marti M; Antonelli T; Tanganelli S; Fuxe K; Ferraro L
Cell Signal; 2017 Dec; 40():116-124. PubMed ID: 28923416
[TBL] [Abstract][Full Text] [Related]
24. Antinociceptive and response rate-altering effects of kappa opioid agonists, spiradoline, enadoline and U69,593, alone and in combination with opioid antagonists in squirrel monkeys.
Pitts RC; Dykstra LA
J Pharmacol Exp Ther; 1994 Dec; 271(3):1501-8. PubMed ID: 7996463
[TBL] [Abstract][Full Text] [Related]
25. Activation of c-fos mRNA in the brain by the kappa-opioid receptor agonist enadoline and the NMDA receptor antagonist dizocilpine.
Panegyres PK; Hughes J
Eur J Pharmacol; 1997 Jun; 328(1):31-6. PubMed ID: 9203564
[TBL] [Abstract][Full Text] [Related]
26. Modulation of pre- and postsynaptic dopamine D2 receptor function by the selective kappa-opioid receptor agonist U69593.
Acri JB; Thompson AC; Shippenberg T
Synapse; 2001 Mar; 39(4):343-50. PubMed ID: 11169785
[TBL] [Abstract][Full Text] [Related]
27. Dynorphin opioid inhibition of cocaine-induced, D1 dopamine receptor-mediated immediate-early gene expression in the striatum.
Steiner H; Gerfen CR
J Comp Neurol; 1995 Mar; 353(2):200-12. PubMed ID: 7745131
[TBL] [Abstract][Full Text] [Related]
28. Kappa agonist-induced reinstatement of cocaine seeking in squirrel monkeys: a role for opioid and stress-related mechanisms.
Valdez GR; Platt DM; Rowlett JK; Rüedi-Bettschen D; Spealman RD
J Pharmacol Exp Ther; 2007 Nov; 323(2):525-33. PubMed ID: 17702903
[TBL] [Abstract][Full Text] [Related]
29. Influence of glial cells in the dopamine releasing effect resulting from the stimulation of striatal delta-opioid receptors.
Billet F; Costentin J; Dourmap N
Neuroscience; 2007 Nov; 150(1):131-43. PubMed ID: 17942234
[TBL] [Abstract][Full Text] [Related]
30. Activation of neuropeptide Y Y1 receptors inhibits glutamate release through reduction of voltage-dependent Ca2+ entry in the rat cerebral cortex nerve terminals: suppression of this inhibitory effect by the protein kinase C-dependent facilitatory pathway.
Wang SJ
Neuroscience; 2005; 134(3):987-1000. PubMed ID: 16026936
[TBL] [Abstract][Full Text] [Related]
31. Discriminative stimulus effects on enadoline in pigeons.
Brandt MR; France CP
J Pharmacol Exp Ther; 1996 May; 277(2):960-7. PubMed ID: 8627579
[TBL] [Abstract][Full Text] [Related]
32. Unexpected inhibitory regulation of glutamate release from rat cerebrocortical nerve terminals by presynaptic 5-hydroxytryptamine-2A receptors.
Wang SJ; Wang KY; Wang WC; Sihra TS
J Neurosci Res; 2006 Nov; 84(7):1528-42. PubMed ID: 17016851
[TBL] [Abstract][Full Text] [Related]
33. Enadoline, a selective kappa-opioid receptor agonist shows potent antihyperalgesic and antiallodynic actions in a rat model of surgical pain.
Field MJ; Carnell AJ; Gonzalez MI; McCleary S; Oles RJ; Smith R; Hughes J; Singh L
Pain; 1999 Mar; 80(1-2):383-9. PubMed ID: 10204752
[TBL] [Abstract][Full Text] [Related]
34. Enadoline and butorphanol: evaluation of kappa-agonists on cocaine pharmacodynamics and cocaine self-administration in humans.
Walsh SL; Geter-Douglas B; Strain EC; Bigelow GE
J Pharmacol Exp Ther; 2001 Oct; 299(1):147-58. PubMed ID: 11561074
[TBL] [Abstract][Full Text] [Related]
35. EEG spectral analysis of the neuroprotective kappa opioids enadoline and PD117302.
Tortella FC; Rose J; Robles L; Moreton JE; Hughes J; Hunter JC
J Pharmacol Exp Ther; 1997 Jul; 282(1):286-93. PubMed ID: 9223566
[TBL] [Abstract][Full Text] [Related]
36. Co-localization and functional interaction between adenosine A(2A) and metabotropic group 5 receptors in glutamatergic nerve terminals of the rat striatum.
Rodrigues RJ; Alfaro TM; Rebola N; Oliveira CR; Cunha RA
J Neurochem; 2005 Feb; 92(3):433-41. PubMed ID: 15659214
[TBL] [Abstract][Full Text] [Related]
37. Effects of kappa opioid agonists alone and in combination with cocaine on heart rate and blood pressure in conscious squirrel monkeys.
Schindler CW; Graczyk Z; Gilman JP; Negus SS; Bergman J; Mello NK; Goldberg SR
Eur J Pharmacol; 2007 Dec; 576(1-3):107-13. PubMed ID: 17707792
[TBL] [Abstract][Full Text] [Related]
38. Comparative effects of selective kappa-opioid receptor agonists on dopamine levels in the dorsal caudate of freely moving rats.
Zaratin P; Clarke GD
Eur J Pharmacol; 1994 Oct; 264(2):151-6. PubMed ID: 7851477
[TBL] [Abstract][Full Text] [Related]
39. Involvement of corticostriatal glutamatergic terminals in striatal dopamine release elicited by stimulation of delta-opioid receptors.
Billet F; Dourmap N; Costentin J
Eur J Neurosci; 2004 Nov; 20(10):2629-38. PubMed ID: 15548206
[TBL] [Abstract][Full Text] [Related]
40. Characterization of kappa opioid receptor mediated, dynorphin-stimulated [35S]GTPγS binding in mouse striatum for the evaluation of selective KOR ligands in an endogenous setting.
Zhou L; Stahl EL; Lovell KM; Frankowski KJ; Prisinzano TE; Aubé J; Bohn LM
Neuropharmacology; 2015 Dec; 99():131-41. PubMed ID: 26160155
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
